Skip to NavigationSkip to content


Alimta recommended as maintenance therapy


NICE has recommended Alimta as a maintenance treatment for people with locally advanced or metastatic non-small cell lung cancer.

Patients must have the non-squamous sub-type of the disease, and to have not progressed immediately following platinum-based chemotherapy first-line chemotherapy.

Alimta (pemetrexed for injection) was approved for the indication in July 2009 in the US and Europe.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches